RLAYHealthcareMid-Cap
Relay Therapeutics, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for Relay Therapeutics, Inc. (RLAY), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud Research Team · SEC Form 4 & insider trading data analysts
Last updated:
Quick Answer
Are RLAY insiders buying or selling?
Relay Therapeutics, Inc. insiders reported 5 open-market buys ($2.2M) and 185 sells ($269.4M) across 190 Form 4 filings — a net selling position of $267.2M.
Source: SEC EDGAR Form 4
Key Statistics (as of Jul 8, 2026)
Total Form 4 filings
190
SEC EDGAR
Insider filers
10
Insider buys (5)
$2.2M
Insider sells (185)
$269.4M
Insider sentiment
Net sellingNet insider flow of $267.2M in net selling.
Recent RLAY insider transactions
| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Donald A Bergstrom | President, R&D | Sale | 8.7K | $18.71 | $162.0K |
| Jul 8, 2026 | Sanjiv Patel | President and CEO | Sale | 48.2K | $19.58 | $943.7K |
| Jul 8, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $18.69 | $331.1K |
| Jul 2, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 50.0K | $19.09 | $954.5K |
| Jun 24, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 187.2K | $16.97 | $3.2M |
| Jun 24, 2026 | Donald A Bergstrom | President, R&D | Sale | 93.5K | $16.94 | $1.6M |
| May 14, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $12.86 | $227.8K |
| Apr 30, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 972 | $14.79 | $14.4K |
| Apr 30, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 753 | $14.79 | $11.1K |
| Apr 30, 2026 | Donald A Bergstrom | President, R&D | Sale | 1.5K | $14.79 | $22.0K |
| Apr 10, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 19.5K | $13.19 | $257.5K |
| Mar 11, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 17.7K | $10.06 | $178.2K |
| Jan 29, 2026 | Donald A Bergstrom | President, R&D | Sale | 21.6K | $7.72 | $166.7K |
| Jan 29, 2026 | Peter Rahmer | Chief Corporate Development Officer | Sale | 13.0K | $7.71 | $100.5K |
| Jan 29, 2026 | Thomas Catinazzo | Chief Financial Officer | Sale | 15.5K | $7.71 | $119.6K |
| Jan 7, 2026 | Sanjiv Patel | President and CEO | Sale | 43.2K | $7.82 | $337.6K |
| Nov 4, 2025 | Sanjiv Patel | President and CEO | Sale | 62.1K | $7.00 | $434.5K |
| Oct 30, 2025 | Peter Rahmer | Chief Corporate Development Officer; Exhibit 24 - Power of Attorney | Sale | 40.5K | $7.40 | $299.9K |
| Oct 30, 2025 | Thomas Catinazzo | Chief Financial Officer | Sale | 21.7K | $7.29 | $157.9K |
| Oct 30, 2025 | Donald A Bergstrom | President, R&D | Sale | 30.9K | $7.29 | $225.2K |
| Jul 30, 2025 | Peter Rahmer | Chief Corporate Develpment Officer | Sale | 17.1K | $3.68 | $62.9K |
| Jul 30, 2025 | Thomas Catinazzo | Chief Financial Officer | Sale | 20.1K | $3.69 | $74.0K |
| Jul 30, 2025 | Donald A Bergstrom | President, R&D | Sale | 30.8K | $3.69 | $113.5K |
| Jul 30, 2025 | Brian Adams | Chief Legal Officer | Sale | 19.9K | $3.68 | $73.4K |
| Jul 10, 2025 | Sanjiv Patel | President and CEO | Sale | 61.4K | $3.57 | $219.1K |
Showing the 25 most recent of 190 Form 4 filings for Relay Therapeutics, Inc..
Most active RLAY insiders
- Donald A Bergstrom51 filings
- Thomas Catinazzo46 filings
- Brian Adams38 filings
- Peter Rahmer27 filings
- Sanjiv Patel16 filings
Ask anything about RLAY insider activity
Use Trabud's AI agent to query Relay Therapeutics, Inc.'s Form 4 history in plain English — "Show me RLAY CEO purchases this year" or compare it against any other ticker.
Open the AI agentRLAY insider trading FAQ
Are Relay Therapeutics, Inc. insiders buying or selling?
Across 190 SEC Form 4 filings, Relay Therapeutics, Inc. (RLAY) insiders reported 5 open-market purchases totaling $2.2M and 185 sales totaling $269.4M. That is a net selling position of $267.2M.
How many insiders trade RLAY stock?
10 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for Relay Therapeutics, Inc.. The most recent filing was accepted on Jul 8, 2026.
Where does Trabud get RLAY insider trading data?
All RLAY insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.
Looking for another company? Browse all tracked companies.